If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,983.00    -32.00 (-1.59%)
Bid:
1,982.50
Ask:
1,983.50
Spread: 1.00 (0.05%)
Market Cap: £79.43b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

15 May 2023 15:30

RNS Number : 4636Z
GSK PLC
15 May 2023
 

GSK plc (the 'Company')

Vesting of 2020 Performance Share Plan Top-Up Award

This notification sets out the vesting details of a "top-up" conditional share award made to the Chief Executive Officer (CEO) on 6 May 2020 under the GSK 2017 Performance Share Plan ('PSP'), following the approval of the 2020 Remuneration Policy at the AGM that year.

This "top-up" PSP award, equivalent to 25% of the CEO's base salary, was made to deliver in aggregate for 2020 an award level of 575% of base salary, increasing her award level from 550%. It was subject to the same business performance conditions as the main 2020 award, with a three-year performance period from 1 January 2020 to 31 December 2022. The main 2020 award vesting was announced on 14 February 2023. The "top-up" award has now vested on the same basis ie 52% vesting 48% lapsed, following the third anniversary of the grant. The vested shares are subject to a further two-year vesting period.

This notification that follows is for the "top-up" award made to the CEO and details the PSP conditional award that vested, including dividends accrued, on 9 May 2023. The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was £14.462.

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on the "top-up" award granted in 2020 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,729

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-05-09

f)

Place of the transaction

 

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFUFLIEDSESI
Date   Source Headline
11th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20237:00 amRNSMomelotinib filing accepted in Japan
1st Sep 20233:00 pmRNSTotal Voting Rights
1st Sep 20237:00 amRNSGSK’s Nucala CRSwNP submission accepted in Japan
31st Aug 20233:16 pmRNSHolding(s) in Company
31st Aug 20233:14 pmRNSHolding(s) in Company
25th Aug 20233:30 pmRNSDirector/PDMR Shareholding
23rd Aug 20233:30 pmRNSDirector/PDMR Shareholding
23rd Aug 20237:00 amRNSShingrix data demonstrate 100% efficacy in China
22nd Aug 20233:30 pmRNSDirector/PDMR Shareholding
10th Aug 20233:30 pmRNSDirector/PDMR Shareholding
9th Aug 20233:30 pmRNSDirector/PDMR Shareholding
8th Aug 20231:05 pmRNSPublication of Base Prospectus
1st Aug 20233:00 pmRNSTotal Voting Rights
31st Jul 20236:00 pmRNSFDA approves new use for Jemperli plus chemo
31st Jul 20233:30 pmRNSDirector/PDMR Shareholding
28th Jul 20233:30 pmRNSDirector/PDMR Shareholding
26th Jul 20237:00 amRNS2nd Quarter Results
24th Jul 20237:00 amRNSCabotegravir LA for PrEP receives positive CHMP
20th Jul 20233:30 pmRNSDirector/PDMR Shareholding
17th Jul 20233:30 pmRNSDirector/PDMR Shareholding
13th Jul 20233:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20233:00 pmRNSTotal Voting Rights
28th Jun 20233:43 pmRNSGSK completes acquisition of BELLUS Health
27th Jun 20237:00 amRNSFDA Fast Track for Gonorrhoea Vaccine Candidate
26th Jun 20237:05 amRNSShingrix approved in Japan for adults 18 and over
26th Jun 20237:00 amRNSGSK daprodustat gains positive EMA CHMP opinion
23rd Jun 20233:37 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:33 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20237:00 amRNSStatement: Zantac (ranitidine) litigation
22nd Jun 20237:00 amRNSGSK’s Arexvy recommended by ACIP
21st Jun 20237:00 amRNSSeason two data for GSK Arexvy RSV OA vaccine
16th Jun 20237:00 amRNSExtension of FDA review period for momelotinib
12th Jun 20233:30 pmRNSDirector/PDMR Shareholding
7th Jun 20237:00 amRNSEU authorisation of GSK’s RSV vaccine Arexvy
6th Jun 20237:00 amRNSGSK receives US FDA file acceptance for Jemperli
1st Jun 20233:00 pmRNSTotal Voting Rights
22nd May 20233:30 pmRNSDirector/PDMR Shareholding
16th May 20232:00 pmRNSHolding(s) in Company
15th May 20233:30 pmRNSDirector/PDMR Shareholding
15th May 20233:00 pmRNSBlock listing Interim Review
12th May 20233:30 pmRNSDirector/PDMR Shareholding
12th May 20239:50 amRNSMenABCWY vaccine preliminary phase III results
12th May 20237:05 amRNSStatement: Zantac Litigation Update BC Canada
12th May 20237:00 amRNSGSK completes sale of shares in Haleon plc
11th May 20234:41 pmRNSGSK announces intention to sell shares in Haleon
9th May 20233:30 pmRNSDirector/PDMR Shareholding
4th May 20233:30 pmRNSDirector/PDMR Shareholding
3rd May 20236:20 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.